Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 5/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184976 | 0.97 | HSP90AA1 (0.41) | HSP90AA1CSF1RPIM1FLT3PIM3 | |
| SCHEMBL2179755 | 0.90 | CHEK2 (0.38) | FLT3CHEK2 | |
| SCHEMBL2185287 | 0.90 | CHEK2 (0.38) | HSP90AA1CHEK2 | |
| SCHEMBL2184560 | 0.90 | CHEK2 (0.38) | FLT3CHEK2 | |
| SCHEMBL2183551 | 0.89 | CHEK2 (0.37) | FLT3CHEK2 | |
| SCHEMBL2181415 | 0.88 | CHEK2 (0.37) | HSP90AA1FLT3CHEK2 | |
| SCHEMBL2185332 | 0.88 | HSP90AA1 (0.40) | HSP90AA1FLT3CHEK2 | |
| SCHEMBL2183773 | 0.88 | CHEK2 (0.36) | HSP90AA1CHEK2 | |
| SCHEMBL2183426 | 0.87 | HSP90AA1 (0.37) | HSP90AA1CHEK2 | |
| SCHEMBL13658333 | 0.87 | CHEK2 (0.36) | HSP90AA1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | claimed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | claimed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| EP-2265598-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009122034-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009122034-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885CSF1R 3453/4885PIM1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.